Skip to content

Pemigatinib

Pemazyre (pemigatinib) is a small molecule pharmaceutical. Pemigatinib was first approved as Pemazyre on 2020-04-17. It is used to treat cholangiocarcinoma in the USA. It has been approved in Europe to treat cholangiocarcinoma. The pharmaceutical is active against fibroblast growth factor receptor 1, fibroblast growth factor receptor 3, and fibroblast growth factor receptor 2. Pemazyre's patents are valid until 2035-01-30 (FDA).
Trade Name Pemazyre
Common Name Pemigatinib
Indication cholangiocarcinoma
Drug Class Tyrosine kinase inhibitors
Pemigatinib
Get full access now